Novartis
NEWS
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
Europe began approving biosimilars in 2006. The U.S. has lagged behind, only starting to approve these copycat drugs in 2015. However, of the nine biosimilars approved in the U.S., only three are actually on the market because of barriers thrown up by the biopharma industry.
Novartis paid far more than $400,000 to President Donald Trump’s lawyer Michael Cohen -- $800,000 more, the company revealed in a statement issued late Wednesday.
Novartis’ generics division, Sandoz, has been struggling in the face of intense pricing pressure. As a result, Novartis has been looking to sell off some of its Sandoz businesses.
Sam Isaly has finally stepped down from his position as a managing member OrbiMed more than four months after he was accused of sexual harassment. Sexual harassment allegations have been in the forefront of the news cycles for months as the #MeToo movement gained traction.
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Sandoz, a division of Novartis, for its Biologics Licensing Application (BLA) for its biosimilar to Roche/Genentech’s Rituxan.
Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Is it possible for the pharma industry to invest too much money into research and development projects for one disease area? In an online essay Jay Bradner, president of Novartis’ Institutes for BioMedical Research, expressed some concern, particularly in areas like cancer research.
JOBS
IN THE PRESS